Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
Rhea-AI Summary
Turn Therapeutics (Nasdaq: TTRX) launched a shareholder communications initiative including a recurring webinar series and a Founder Blog by CEO Bradley Burnam.
The first live webinar is scheduled for October 22, 2025 at 2:00 PM ET via webcast; recordings and materials will be posted to the investor relations website immediately after each session. The Founder Blog will share ongoing company updates, research insights, and perspectives, with additional blog details to be announced later this week.
Turn notes three FDA clearances for its wound and dermatology formulations and ongoing late-stage clinical programs in eczema and onychomycosis.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TTRX declined 2.37%, reflecting a moderate negative market reaction. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $135M at that time.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.
“It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader healthcare community,” said Bradley Burnam, Founder and CEO of Turn Therapeutics. “But this company was built by a deeply engaged community, and we intend to continue that conversation as we grow.”
The Founder Blog will publicly share ongoing company updates, research insights, and perspectives on Turn’s growth and innovation. Further details about the blog will be announced later this week. The webinar series will provide live discussion covering ongoing programs, strategic milestones, and upcoming developments. The first live session will take place on Wednesday, October 22, 2025, at 2:00 PM ET via webcast.
Recordings and materials from webinars will be posted immediately following each session to the investor relations section of the company website.
October 22, 2025 live webinar:
Time: 2PM EST
Location: Click here to join
RSVP/Registration: Not required
About Turn Therapeutics
Turn Therapeutics is a biotechnology company developing and commercializing products for dermatology, wound care, and infectious disease. The company has received three FDA clearances for its proprietary wound and dermatology formulations and is advancing late-stage clinical programs in eczema and onychomycosis. In addition, Turn is pursuing global health initiatives in thermostable vaccine delivery designed to serve underserved areas worldwide, reflecting its commitment to public health innovation.
Where You Can Find Additional Information
Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://ir.turntherapeutics.com), filings we make with the Securities and Exchange Commission (the “SEC”), our corporate account on the social media platform X (formerly Twitter) (@hexagenhealing), LinkedIn, other social media platforms, webcasts, press releases and conference calls. We use these mediums to communicate with our shareholders and the public about our company and other matters. It is possible that the information that we make available in this manner may be deemed to be material information. We therefore encourage investors and others interested in our company to review this information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. These statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the timing and effectiveness of the Company’s registration statement, the success of development programs, and the Company’s ability to execute its strategic plan. Further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these statements can be found in the Company’s SEC filings. Turn undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact: media@TurnTherapeutics.com
Investor Relations: investors@TurnTherapeutics.com
FAQ
When is Turn Therapeutics (TTRX) hosting its first shareholder webinar?
Do investors need to register to attend the Turn Therapeutics (TTRX) October 22, 2025 webinar?
Where will Turn Therapeutics (TTRX) post webinar recordings and materials after the October 22, 2025 session?
What will CEO Bradley Burnam cover in the new Founder Blog for Turn Therapeutics (TTRX)?
What regulatory progress has Turn Therapeutics (TTRX) announced in the press release?
Which clinical programs did Turn Therapeutics (TTRX) note when launching the webinar series on October 20, 2025?
